Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation-Reference-Cited by-同舟云学术

Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation

Published:2018-04 Issue:4 Volume:10 Page:2166-2178
ISSN:2072-1439
Container-title:Journal of Thoracic Disease
language:
Short-container-title:J. Thorac. Dis.

Author:

Barrón Feliciano, ,Cardona Andrés F.,Corrales Luis,Ramirez-Tirado Laura-Alejandra,Caballe-Perez Enrique,Sanchez Gisela,Flores-Estrada Diana,Zatarain-Barrón Zyanya Lucia,Arrieta Oscar

Publisher

AME Publishing Company

Subject

Pulmonary and Respiratory Medicine

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer;Biomedicines;2024-07-05

2. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients;Oncology Letters;2023-06-13

3. Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer;Cancer Medicine;2023-04-25

4. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia;Romanian Journal of Internal Medicine;2023-03-01

5. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population;Lung Cancer;2022-12